{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=22&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Gilbert",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 991,
    "total_pages": 100,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=23&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=21&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T03:40:07.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06272487",
      "title": "Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Cardiovascular Risk",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Zilebesiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-02-29",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 139,
      "location_summary": "Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06272487"
    },
    {
      "nct_id": "NCT07875413",
      "title": "Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Large B Cell Lymphoma",
        "LBCL",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Relapse Diffuse Large B Cell Lymphoma",
        "High Grade B Cell Lymphoma",
        "FL",
        "HGBL",
        "Transformed Follicular Lymphoma (TFL)",
        "Primary Mediastinal B Cell Lymphoma",
        "PMBCL",
        "HGBL With MYC and BCL2 and/or BCL6 Rearrangements"
      ],
      "interventions": [
        {
          "name": "Prizloncabtagene Autoleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbelZeta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2027-05",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 2,
      "location_summary": "Gilbert, Arizona • La Jolla, California",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07875413"
    },
    {
      "nct_id": "NCT06661720",
      "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Renal Cell Carcinoma (RCC)",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tivozanib",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1040,
      "start_date": "2025-03-14",
      "completion_date": "2037-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 429,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06661720"
    },
    {
      "nct_id": "NCT02705105",
      "title": "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Cancer",
        "Carcinoma",
        "Hepatocellular Carcinoma",
        "HCC"
      ],
      "interventions": [
        {
          "name": "Mogamulizumab + Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2016-02",
      "completion_date": "2018-10-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 15,
      "location_summary": "Gilbert, Arizona • Greenbrae, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02705105"
    },
    {
      "nct_id": "NCT03367702",
      "title": "Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage II Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 698,
      "start_date": "2018-02-01",
      "completion_date": "2027-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 276,
      "location_summary": "Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367702"
    },
    {
      "nct_id": "NCT00477672",
      "title": "A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease Psychosis"
      ],
      "interventions": [
        {
          "name": "Pimavanserin tartrate (ACP-103)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2007-06",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-17",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 36,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Carson",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477672"
    },
    {
      "nct_id": "NCT00096928",
      "title": "A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1846,
      "start_date": "2005-03",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 182,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096928"
    },
    {
      "nct_id": "NCT04596033",
      "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "GEN-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-11-11",
      "completion_date": "2022-06-27",
      "has_results": false,
      "last_update_posted_date": "2022-07-15",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04596033"
    },
    {
      "nct_id": "NCT05712200",
      "title": "Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2022-12-27",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 174,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 143 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712200"
    },
    {
      "nct_id": "NCT04885530",
      "title": "ACTIV-6: COVID-19 Study of Repurposed Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Montelukast",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Susanna Naggie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 10956,
      "start_date": "2021-06-08",
      "completion_date": "2024-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-11-20T03:40:07.262Z",
      "location_count": 110,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04885530"
    }
  ]
}